Abarelix
 | |
| Systematic (IUPAC) name | |
|---|---|
|
acetyl-D-β-naphthylalanyl- D-4-chlorophenylalanyl-D-3-pyridylalanyl-L-seryl-L- N-methyl- tyrosyl-D-asparagyl-L-leucyl-L-N(e )-isopropyl-lysyl-L-prolyl-D-alanyl-amide | |
| Clinical data | |
| Trade names | Plenaxis |
| AHFS/Drugs.com | monograph |
| Pregnancy category |
|
| Routes of administration | Intramuscular injection |
| Pharmacokinetic data | |
| Protein binding | 96–99% |
| Identifiers | |
| CAS Number |
183552-38-7  |
| ATC code | L02BX01 |
| PubChem | CID 16131215 |
| IUPHAR/BPS | 1188 |
| DrugBank |
DB00106  |
| ChemSpider |
10482301 |
| UNII |
W486SJ5824 |
| KEGG |
D02738 |
| ChEBI |
CHEBI:337298 |
| ChEMBL |
CHEMBL1252 |
| Chemical data | |
| Formula | C72H95ClN14O14 |
| Molar mass | 1416.06 g/mol |
| |
| |
| (what is this?) (verify) | |
Abarelix (trade name Plenaxis) is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available.[1][2]
It was originally marketed by Praecis Pharmaceuticals as Plenaxis,[1] and is now marketed by Speciality European Pharma in Germany[3] after receiving a marketing authorisation in 2005.
References
- 1 2 Drugs.com: Abarelix
- ↑ Boccon-Gibod, L.; Van Der Meulen, E.; Persson, B. -E. (2011). "An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer". Therapeutic Advances in Urology 3 (3): 127–140. doi:10.1177/1756287211414457. PMC 3159401. PMID 21904569.
- ↑ Pharmazeutische Zeitung online: Abarelix (German)
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Thursday, August 27, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.